Robert E Landry Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Robert E Landry is EVP Finance CFO of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 23,693 shares of REGN, which is worth approximately $12.3 Million. The most recent transaction as insider was on Apr 02, 2020, when has been sold 2,317 shares (Common Stock) at a price of $492.05 per share, resulting in proceeds of $1,140,079. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 23.7K

0% 3M change

0% 12M change

Total Value Held $12.3 Million

Robert E Landry Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 02 2020	SELL Payment of exercise price or tax liability	$1,140,079 $492.05 p/Share	2,317 Reduced 8.07%	26,409 Common Stock
Apr 02 2020	SELL Open market or private sale	$52,114 $496.33 p/Share	105 Reduced 0.42%	25,056 Common Stock
Apr 02 2020	BUY Exercise of conversion of derivative security	$818,100 $272.7 p/Share	3,000 Added 9.46%	28,726 Common Stock
Apr 01 2020	SELL Payment of exercise price or tax liability	$2,268,711 $488.21 p/Share	4,647 Reduced 15.3%	25,726 Common Stock
Apr 01 2020	SELL Open market or private sale	$291,924 $486.54 p/Share	600 Reduced 2.4%	24,373 Common Stock
Apr 01 2020	BUY Exercise of conversion of derivative security	$1,636,200 $272.7 p/Share	6,000 Added 18.24%	26,888 Common Stock
Feb 26 2020	SELL Open market or private sale	$91,198 $455.99 p/Share	200 Reduced 0.79%	24,973 Common Stock
Feb 25 2020	SELL Open market or private sale	$96,015 $448.67 p/Share	214 Reduced 0.84%	25,173 Common Stock
Feb 25 2020	SELL Payment of exercise price or tax liability	$357,840 $447.3 p/Share	800 Reduced 3.05%	25,387 Common Stock
Feb 25 2020	BUY Exercise of conversion of derivative security	$272,700 $272.7 p/Share	1,000 Added 3.68%	26,187 Common Stock
Feb 24 2020	SELL Payment of exercise price or tax liability	$319,579 $406.59 p/Share	786 Reduced 3.03%	25,187 Common Stock
Feb 24 2020	BUY Exercise of conversion of derivative security	$272,700 $272.7 p/Share	1,000 Added 3.71%	25,973 Common Stock
Feb 13 2020	SELL Open market or private sale	$42,991 $401.79 p/Share	107 Reduced 0.43%	24,973 Common Stock
Feb 12 2020	SELL Payment of exercise price or tax liability	$158,119 $402.34 p/Share	393 Reduced 1.54%	25,080 Common Stock
Feb 12 2020	BUY Exercise of conversion of derivative security	$136,350 $272.7 p/Share	500 Added 1.93%	25,473 Common Stock

Also insider at

CYTK

CYTOKINETICS INC Healthcare

Director

REL

Robert E Landry

EVP Finance CFO

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account